TY - JOUR
T1 - Temporal trends in population characteristics and type of device among primary prevention implantable cardioverter defibrillator recipients
T2 - The DAI-PP programme
AU - Frodi, Diana My
AU - Boveda, Serge
AU - Fournier, Victor
AU - Kerkouri, Fawzi
AU - Anselme, Frederic
AU - Deharo, Jean-Claude
AU - Extramiana, Fabrice
AU - Fauchier, Laurent
AU - Gandjbakhch, Estelle
AU - Gras, Daniel
AU - Hermida, Alexis
AU - Jesel-Morel, Laurence
AU - Leclercq, Christophe
AU - Lellouche, Nicolas
AU - Menet, Aymeric
AU - Narayanan, Kumar
AU - Piot, Olivier
AU - Probst, Vincent
AU - Sadoul, Nicolas
AU - Taieb, Jerome
AU - Defaye, Pascal
AU - Marijon, Eloi
AU - Garcia, Rodrigue
AU - behalf of the DAI-PP investigators
N1 - Copyright © 2025. Published by Elsevier Masson SAS.
PY - 2025/3
Y1 - 2025/3
N2 - BACKGROUND: Patient characteristics, technology and clinical practice surrounding primary prevention implantable cardioverter defibrillators have evolved continuously over time.AIM: To explore the temporal changes in patient characteristics, pharmacological therapy and device types among implantable cardioverter defibrillator recipients implanted for the primary prevention of sudden cardiac death over the last two decades in France.METHODS: Characteristics of participants and type of device from the retrospective DAI-PP Pilot Study (2002-2012) were compared with those from the ongoing prospective DAI-PP Consortium (2018 onwards).RESULTS: This study included 9588 participants overall (DAI-PP Pilot Study, n=5539; DAI-PP Consortium, n=4049). Compared with the DAI-PP Pilot Study, the DAI-PP Consortium subjects were older at implantation (62.5 vs 65.2 years; P=0.001) and had a higher proportion of women (15.1% vs 20.6%; P<0.001), a similar proportion of ischaemic heart disease (60.2% vs 60.2%; P=0.98), a higher left ventricular ejection fraction (27±7% vs 30±8%; P<0.001) and more patients with narrow QRS complexes (30.5% vs 46.0%; P<0.001). The proportion of patients treated with heart failure drugs increased significantly (70.1% vs 83.1%; P<0.001), whereas the use of amiodarone became much less frequent (22.7% vs 14.7%; P<0.001). Finally, the proportions of cardiac resynchronization therapy defibrillators (53.8% vs 46.4%; P<0.001) and dual-chamber defibrillators (23.3% vs 17.3%; P<0.001) decreased, whereas subcutaneous implantable cardioverter defibrillators now account for a sizeable proportion of implants (14.6%).CONCLUSIONS: Over a 20-year period, the primary prevention implantable cardioverter defibrillator population has evolved significantly, with an older age and a higher proportion of women. The type of device has changed, with fewer cardiac resynchronization therapy defibrillators and more subcutaneous implantable cardioverter defibrillators.
AB - BACKGROUND: Patient characteristics, technology and clinical practice surrounding primary prevention implantable cardioverter defibrillators have evolved continuously over time.AIM: To explore the temporal changes in patient characteristics, pharmacological therapy and device types among implantable cardioverter defibrillator recipients implanted for the primary prevention of sudden cardiac death over the last two decades in France.METHODS: Characteristics of participants and type of device from the retrospective DAI-PP Pilot Study (2002-2012) were compared with those from the ongoing prospective DAI-PP Consortium (2018 onwards).RESULTS: This study included 9588 participants overall (DAI-PP Pilot Study, n=5539; DAI-PP Consortium, n=4049). Compared with the DAI-PP Pilot Study, the DAI-PP Consortium subjects were older at implantation (62.5 vs 65.2 years; P=0.001) and had a higher proportion of women (15.1% vs 20.6%; P<0.001), a similar proportion of ischaemic heart disease (60.2% vs 60.2%; P=0.98), a higher left ventricular ejection fraction (27±7% vs 30±8%; P<0.001) and more patients with narrow QRS complexes (30.5% vs 46.0%; P<0.001). The proportion of patients treated with heart failure drugs increased significantly (70.1% vs 83.1%; P<0.001), whereas the use of amiodarone became much less frequent (22.7% vs 14.7%; P<0.001). Finally, the proportions of cardiac resynchronization therapy defibrillators (53.8% vs 46.4%; P<0.001) and dual-chamber defibrillators (23.3% vs 17.3%; P<0.001) decreased, whereas subcutaneous implantable cardioverter defibrillators now account for a sizeable proportion of implants (14.6%).CONCLUSIONS: Over a 20-year period, the primary prevention implantable cardioverter defibrillator population has evolved significantly, with an older age and a higher proportion of women. The type of device has changed, with fewer cardiac resynchronization therapy defibrillators and more subcutaneous implantable cardioverter defibrillators.
KW - Aged
KW - Arrhythmias, Cardiac/therapy
KW - Cardiac Resynchronization Therapy Devices/trends
KW - Death, Sudden, Cardiac/prevention & control
KW - Defibrillators, Implantable
KW - Electric Countershock/instrumentation
KW - Female
KW - France/epidemiology
KW - Humans
KW - Male
KW - Middle Aged
KW - Pilot Projects
KW - Primary Prevention/instrumentation
KW - Prospective Studies
KW - Prosthesis Design
KW - Retrospective Studies
KW - Risk Factors
KW - Time Factors
KW - Treatment Outcome
KW - Implantable cardioverter defibrillator
KW - Temporal trends
KW - Sudden cardiac death
KW - Baseline characteristics
KW - Primary prevention
UR - https://www.scopus.com/pages/publications/85216685703
U2 - 10.1016/j.acvd.2024.10.335
DO - 10.1016/j.acvd.2024.10.335
M3 - Journal article
C2 - 39890483
SN - 1875-2128
VL - 118
SP - 178
EP - 184
JO - Archives of cardiovascular diseases
JF - Archives of cardiovascular diseases
IS - 3
ER -